Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1952 6
1953 1
1956 6
1957 1
1958 1
1959 1
1961 5
1962 5
1963 12
1964 15
1965 10
1966 17
1967 22
1968 27
1969 21
1970 30
1971 38
1972 35
1973 45
1974 35
1975 44
1976 33
1977 45
1978 87
1979 51
1980 81
1981 91
1982 89
1983 94
1984 94
1985 109
1986 112
1987 137
1988 161
1989 178
1990 166
1991 179
1992 202
1993 172
1994 186
1995 198
1996 196
1997 195
1998 204
1999 237
2000 256
2001 282
2002 271
2003 294
2004 306
2005 320
2006 319
2007 282
2008 335
2009 343
2010 322
2011 326
2012 363
2013 344
2014 347
2015 357
2016 384
2017 432
2018 451
2019 480
2020 517
2021 578
2022 543
2023 454
2024 443
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,990 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. Among authors: kobayashi k. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.
Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Iizaki Y, Maseki N, Kawamura M, Kobayashi K, Nishimura Y, Kanda H, Nitta H, Noguchi M, Kobayashi H. Sekiguchi Y, et al. Among authors: kobayashi k. J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043. J Clin Exp Hematop. 2023. PMID: 38148017 Free PMC article. No abstract available.
Structure of the miniature type V-F CRISPR-Cas effector enzyme.
Takeda SN, Nakagawa R, Okazaki S, Hirano H, Kobayashi K, Kusakizako T, Nishizawa T, Yamashita K, Nishimasu H, Nureki O. Takeda SN, et al. Among authors: kobayashi k. Mol Cell. 2021 Feb 4;81(3):558-570.e3. doi: 10.1016/j.molcel.2020.11.035. Epub 2020 Dec 16. Mol Cell. 2021. PMID: 33333018 Free article.
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. Jänne PA, et al. Among authors: kobayashi k. J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2. J Clin Oncol. 2024. PMID: 38042525 Free PMC article. Clinical Trial.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: kobayashi k. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Among authors: kobayashi k. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
Structural basis for lysophosphatidylserine recognition by GPR34.
Izume T, Kawahara R, Uwamizu A, Chen L, Yaginuma S, Omi J, Kawana H, Hou F, Sano FK, Tanaka T, Kobayashi K, Okamoto HH, Kise Y, Ohwada T, Aoki J, Shihoya W, Nureki O. Izume T, et al. Among authors: kobayashi k. Nat Commun. 2024 Feb 7;15(1):902. doi: 10.1038/s41467-024-45046-z. Nat Commun. 2024. PMID: 38326347 Free PMC article.
Epigenetic Mechanisms Underlying COVID-19 Pathogenesis.
Kaneko S, Takasawa K, Asada K, Shinkai N, Bolatkan A, Yamada M, Takahashi S, Machino H, Kobayashi K, Komatsu M, Hamamoto R. Kaneko S, et al. Among authors: kobayashi k. Biomedicines. 2021 Sep 2;9(9):1142. doi: 10.3390/biomedicines9091142. Biomedicines. 2021. PMID: 34572329 Free PMC article. Review.
Neural mechanisms of information seeking.
Kobayashi K, Kable JW. Kobayashi K, et al. Neuron. 2024 Jun 5;112(11):1741-1756. doi: 10.1016/j.neuron.2024.04.008. Epub 2024 May 3. Neuron. 2024. PMID: 38703774 Review.
11,990 results
You have reached the last available page of results. Please see the User Guide for more information.